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Introduction
Background
Escherichia coli is the commonest organism to be isolated in 
blood cultures in the UK and elsewhere in Europe1–3. Whilst 
rates of MRSA bacteraemia have been decreasing over the 
past few years, Escherichia coli bacteraemia (ECB) has been 
consistently increasing3,4. This is a worrying phenomenon, as 
antimicrobial resistance (AMR) in Escherichia coli and other 
Enterobacteriaceae makes invasive infections progressively more 
difficult to treat5. Whilst an infection in any part of the body 
has the potential to cause a bloodstream infection, the major-
ity (approximately 50%) of ECB are from a urinary source1,4. 
Other sources include an infection in the gastrointestinal or 
biliary tract, and less commonly respiratory tract infection. 
A small proportion of ECB also has an unidentified source1.
Rates of ECB are highest in young children and the elderly, and 
have been shown to vary with the seasons, in a way which has 
not been identified in, for example, MRSA bacteraemia6. The 
risk factors for ECB are not well described. As most ECB is 
community acquired, it has been argued that there is limited 
scope for preventative strategies. Recent studies, however, 
show that a large proportion of community-acquired cases are 
healthcare associated, with patients having had contact with 
hospital or outpatient services7. This potentially increases the 
scope for interventions that could reduce their incidence.
Rationale for the review
Rates of AMR are rising globally and are of great concern to 
clinicians and policy-makers as they are associated with higher 
morbidity and mortality, longer healthcare stays and higher 
healthcare costs8,9. In light of this, the trend for increasing 
rates of ECB is troubling. Given that most ECB is community- 
acquired, any interventions to reduce these rates must be based 
on robust evidence of the risk factors contributing to its acqui-
sition. AMR is driven by antibacterial use, whether this is 
appropriate or inappropriate, and judicious antibacterial use 
must be based on information on which patients are more or less 
likely to suffer a severe outcome from their infection.
To our knowledge, no systematic review to date has investi-
gated the risk factors for community-acquired ECB. This review 
therefore aims to provide a systematic synthesis of the available 
published evidence. The results may inform community inter-
ventions to reduce ECB, as well as inform antibiotic prescribing 
policy.
Objectives
The objective of this review is to investigate the risk factors 
for developing community-acquired Escherichia coli bacterae-
mia in patients of all ages in high income countries (as defined 
by the World Bank).
Protocol
This study protocol follows the recommendations by the Pre-
ferred Reporting Items for Systematic Review and Meta-Analysis 
Protocols (PRISMA-P) 201510. A completed PRISMA-P checklist 
can be found in Supplementary File 1.
Eligibility criteria
Study designs. Observational and experimental primary research 
studies will be eligible for inclusion. The following study 
designs will be considered: cohort, case-control and cross- 
sectional studies; randomised and non-randomised, controlled 
and non-controlled trials; reviews and meta-analyses (as a 
means of identifying the source studies). Only studies which 
include a control group who did not have community-acquired 
ECB will be included. We will exclude case reports, case series, 
opinion papers, letters to the editor, policy papers, conference 
proceedings, comments and study protocols without baseline 
data.
Participants. We will include participants of all ages who were 
admitted to hospital with community-acquired ECB.
Exposures. There will be no restrictions on the types of expo-
sures (risk factors) considered in the primary studies, and 
studies will be considered provided they include quantitative 
data on the risk factors for community-acquired ECB. Potential 
risk factors may include clinical features, demographic char-
acteristics, dehydration, presence of a urinary catheter, prior 
hospital contact, prior antibiotic usage and co-morbidities such 
as diabetes mellitus and chronic kidney disease.
Comparators. The main comparator will be participants without 
bacteraemia. However, as we are aiming to include a broad 
range of studies, control groups may include participants with 
hospital-acquired ECB and participants with community-
acquired bacteraemia due to another organism(s). A control 
group of participants with hospital-acquired ECB will allow us 
to identify risk factors specifically associated with acquisition 
of ECB in the community – potentially leading to interventions 
in primary care or public health campaigns. A control group 
of participants with community-acquired bacteraemia due to 
another organism will allow us to identify risk factors specifi-
cally associated with Escherichia coli itself, potentially informing 
antibiotic treatment strategies.
Studies which assess particular clinical conditions, for exam-
ple malignancy, in relation to community-acquired ECB will 
be included if they also include a control group which does not 
have the condition of interest. Studies comparing one antibiotic 
regimen against another in treating community-acquired ECB 
will also be included if they fit the other eligibility criteria.
Outcome measures. The outcome will be community-acquired 
ECB, as defined by a blood culture which is positive for 
Escherichia coli within +/- 1 day of admission to hospital.
Time frame. There will be no restriction by duration of follow- 
up or date of publication.
Setting. Only studies carried out in high income countries (as 
defined by the World Bank) will be included11.
Language. Only studies published in English will be included.
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Information sources
The following databases will be searched: Medline, Embase, 
Web of Science/Scopus and the Cochrane database. Each data-
base will be searched separately and the search strategy first 
developed in Medline will be adapted to each database interface 
as appropriate. Relevant studies from the reference lists of 
the eligible studies identified through the electronic searches 
will also be included.
Search strategy
The above databases will be searched for the above dates for rel-
evant studies. The literature search will use the following terms 
(with synonyms and closely related words): “Escherichia coli” 
AND “bacteraemia” AND “community-acquired infections”. The 
searches will not be limited by study design, but will be limited 
to those undertaken in high-income countries (as defined by 
the World Bank) and published in English11. The search strat-
egy for Medline is outlined in Table 1. The full list of sources 
and search strategies used can be found in Supplementary File 2.
Study records: data management, selection process, data 
collection process
The search results will be uploaded into the Mendeley reference 
management software, and duplicate records will be removed. 
The study records will then be uploaded into DistillerSR, a 
web-based systematic review management software. Studies 
will be screened for eligibility by two independent reviewers 
(A.A. and S.H.). Data will be extracted from the reports using 
specifically designed data extraction forms which will be 
piloted prior to use. Data will be extracted independently and in 
duplicate by the two reviewers. Discrepancies will be discussed 
with a third reviewer (L.S.) and agreed by consensus. Where 
necessary, clarification will be sought from study investigators. 
The study selection process will be recorded and presented in 
flow diagram format according to the recommendations of 
PRISMA.
Data items
Data will be sought for the following variables:
•    Study characteristics (design, location, year of 
recruitment)
•    Study participants: inclusion and exclusion criteria, 
method of recruitment/selection, study population 
characteristics (age, gender, socioeconomic group, co- 
morbidities, residential/nursing home resident)
•    Identified exposures (risk factors) e.g. urinary catheter 
use, interventional procedures, dehydration, prior 
admissions to hospital, prior/recurrent UTI, pregnancy
•    Bacteraemia data: date of blood culture in relation to 
admission, antibiotic sensitivities of Escherichia coli 
Table 1. Preliminary Ovid (Medline and Embase) search strategy.
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isolate, source of bacteraemia (urinary, GI/biliary, respiratory, 
cardiovascular, unknown/unspecified)
•    Interventions and comparators: antibiotic regimen and 
duration, level of care (general ward/ICU/outpatient 
treatment), follow-up time.
Outcomes and prioritisation
The only outcome of interest for this systematic review is 
community-acquired ECB. Multiple exposures will, however, be 
considered, with potentially modifiable exposures, for example 
urinary catheter use and dehydration, taking priority.
Risk of bias in this review and individual studies
We will conduct the systematic review in accordance with 
this protocol, and any differences between the methods of the 
complete review and this protocol will be reported in the review.
Risk of bias will be assessed using the Newcastle-Ottawa scale 
for non-randomised studies, and the Cochrane Risk of Bias Tool 
for randomised controlled trials12,13. Each study will be inde-
pendently assessed by A.A. and S.H. for selection, performance, 
attrition and reporting bias, and disagreements will be resolved 
by discussion and consensus. If consensus cannot be reached, 
a third reviewer (L.S.) will be consulted to adjudicate.
Data synthesis
Formal meta-analysis will be carried out only if we identify 
two or more studies which we consider homogenous in terms 
of clinical characteristics, study design and methods. In this 
case we will synthesise the available information using random 
effects meta-analysis, and report on factors positively or 
negatively associated with development of ECB using risk 
ratios, odds ratios or rate ratios (depending on study design) 
with 95% confidence intervals. If there are insufficient stud-
ies for meta-analysis, we will synthesise the data narratively. 
The outcomes will be analysed at the level of individual study 
participants for each study, and we will attempt to obtain any 
missing numerical outcome data by contacting investigators 
directly. We will explore the impact of including studies with 
high levels of missing outcome data on the measure of associa-
tion in sensitivity analyses. We will assess heterogeneity between 
studies by presenting a forest plot of the review outcome, and 
will then calculate the formal heterogeneity variance statistics 
τ2, I2 and the Q-statistic. Heterogeneity will be considered as 
substantial if the τ2 is greater than 0, I2 is more than 30% and 
the P value for the Q-statistic is less than 0.10.
Assessment of publication bias
We will assess publication bias by visual inspection of funnel 
plots.
Assessment of strength of evidence
We will use the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) framework to assess the 
strength of the body of evidence for this systematic review14.
Ethics and dissemination
No primary data will be collected for this study and so formal 
ethical approval is not required. We will publish the results of 
our review in relevant peer-reviewed medical journals, and will also 
seek to present them at relevant medical conferences.
Data availability
No data are associated with this article.
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